MiMedx Group Inc  

(Public, NASDAQ:MDXG)   Watch this stock  
-0.31 (-3.80%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.80 - 8.14
52 week 6.71 - 13.20
Open 8.11
Vol / Avg. 1.24M/990,861.00
Mkt cap 889.13M
P/E 45.15
Div/yield     -
EPS 0.17
Shares 108.96M
Beta 0.76
Inst. own 46%
Apr 25, 2016
Q1 2016 MiMedx Group Inc Earnings Release (Estimated) Add to calendar
Jan 14, 2016
MiMedx Group Inc at JPMorgan Healthcare Conference
Jan 11, 2016
Q4 2015 MiMedx Group Inc Earnings and Agreement To Acquire Stability Biologics Call - Webcast
Jan 10, 2016
Q4 2015 MiMedx Group Inc Earnings Release
Dec 17, 2015
MIMEDX GROUP INC 2016 Outlook Conference Call - Webcast
Dec 9, 2015
MiMedx Group Inc at Oppenheimer Healthcare Conference
Dec 2, 2015
MiMedx Group Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 19, 2015
MiMedx Group Inc at Canaccord Genuity Medical Technology & Diagnostics Forum
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 13.37% 5.26%
Operating margin 13.70% 6.01%
EBITD margin - 7.80%
Return on average assets 21.92% 6.41%
Return on average equity 27.12% 7.64%
Employees 386 -
CDP Score - -


1775 W Oak Commons Ct
MARIETTA, GA 30062-2254
United States - Map
+1-678-3846720 (Phone)
+1-678-3846720 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


MiMedx Group, Inc. (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Company's biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program, mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant, which is referred as an allograft. MiMedx is the supplier of amniotic tissue, having supplied over 350,000 allografts for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.

Officers and directors

Parker H. Petit Jr. Chairman of the Board, Chief Executive Officer
Age: 75
Bio & Compensation  - Reuters
William Charles Taylor President, Chief Operating Officer, Director
Age: 46
Bio & Compensation  - Reuters
Michael J. Senken Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Alexandra O. Haden General Counsel, Secretary
Age: 40
Bio & Compensation  - Reuters
Charles E. Koob Director
Age: 70
Bio & Compensation  - Reuters
Joseph G. Bleser Independent Director
Age: 69
Bio & Compensation  - Reuters
J. Terry Dewberry Independent Director
Bio & Compensation  - Reuters
Charles R. Evans Independent Director
Age: 68
Bio & Compensation  - Reuters
Bruce L. Hack Independent Director
Age: 66
Bio & Compensation  - Reuters